🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Cliff Asness’s LENZ Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+140,305 Shares
Current Position
140,305 Shares
$1.28 M Value

Cliff Asness's LENZ Position Overview

Cliff Asness (via Aqr Capital Management LLC) currently holds 140,305 shares of LENZ Therapeutics, Inc. (LENZ) worth $1.28 M, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Cliff Asness has initiated a new position in LENZ, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Cliff Asness's LENZ Therapeutics (LENZ) Holding Value Over Time

Track share changes against reported price movement

Quarterly LENZ Therapeutics (LENZ) Trades by Cliff Asness

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +140,305 New Buy 140,305 $9.15

Cliff Asness's LENZ Therapeutics Investment FAQs

Cliff Asness first purchased LENZ Therapeutics, Inc. (LENZ) in Q1 2026, acquiring 140,305 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Cliff Asness has held LENZ Therapeutics, Inc. (LENZ) for 1 quarters since Q1 2026.

Cliff Asness's largest addition to LENZ Therapeutics, Inc. (LENZ) was in Q1 2026, adding 140,305 shares worth $1.28 M.

According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 140,305 shares of LENZ Therapeutics, Inc. (LENZ), valued at approximately $1.28 M.

As of the Q1 2026 filing, LENZ Therapeutics, Inc. (LENZ) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.

Cliff Asness's peak holding in LENZ Therapeutics, Inc. (LENZ) was 140,305 shares, as reported at the end of Q1 2026.